Anemia in chronic kidney disease

Meredith Atkinson, Bradley A. Warady

Research output: Contribution to journalArticle

Abstract

Anemia is common and associated with adverse outcomes in children with chronic kidney disease (CKD). Many factors contribute to declining hemoglobin as CKD progresses, but impaired production of erythropoietin by failing kidneys is a central cause. Hepcidin-mediated iron restriction also contributes to anemia by downregulating both intestinal iron absorption and release of stored iron for erythropoiesis. The core components of anemia management remain erythropoiesis-stimulating agents (ESA) and iron supplementation, but despite these therapies, a substantial number of children remain anemic. Although escalating ESA dose to target higher hemoglobin has been associated with adverse outcomes in adults, no trials have investigated this association in children, and maintaining hemoglobin levels in a narrow range with conservative ESA dosing is challenging. Judicious use of iron supplementation can enhance the response to ESAs, but the iron storage markers most commonly used in clinical practice have limitations in distinguishing which patients will benefit most from additional iron. Several novel anemia therapies, including hypoxia-inducible factor stabilizers, prolyl hydroxylase inhibitors, and dialysate-delivered iron supplements, have been developed and may offer options for alternative anemia management. However, the safety and efficacy of these agents in children with CKD has yet to be assessed.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalPediatric Nephrology
DOIs
StateAccepted/In press - Apr 15 2017

Fingerprint

Chronic Renal Insufficiency
Anemia
Iron
Hematinics
Hemoglobins
Prolyl-Hydroxylase Inhibitors
Hepcidins
Erythropoiesis
Dialysis Solutions
Intestinal Absorption
Erythropoietin
Down-Regulation
Kidney
Safety
Therapeutics

Keywords

  • Anemia
  • Erythropoiesis-stimulating agent
  • Hemoglobin
  • Hepcidin
  • Iron-restricted erythropoiesis

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Anemia in chronic kidney disease. / Atkinson, Meredith; Warady, Bradley A.

In: Pediatric Nephrology, 15.04.2017, p. 1-12.

Research output: Contribution to journalArticle

Atkinson, Meredith ; Warady, Bradley A. / Anemia in chronic kidney disease. In: Pediatric Nephrology. 2017 ; pp. 1-12.
@article{79b1e661b89e44b4b18f22c2324fe2d8,
title = "Anemia in chronic kidney disease",
abstract = "Anemia is common and associated with adverse outcomes in children with chronic kidney disease (CKD). Many factors contribute to declining hemoglobin as CKD progresses, but impaired production of erythropoietin by failing kidneys is a central cause. Hepcidin-mediated iron restriction also contributes to anemia by downregulating both intestinal iron absorption and release of stored iron for erythropoiesis. The core components of anemia management remain erythropoiesis-stimulating agents (ESA) and iron supplementation, but despite these therapies, a substantial number of children remain anemic. Although escalating ESA dose to target higher hemoglobin has been associated with adverse outcomes in adults, no trials have investigated this association in children, and maintaining hemoglobin levels in a narrow range with conservative ESA dosing is challenging. Judicious use of iron supplementation can enhance the response to ESAs, but the iron storage markers most commonly used in clinical practice have limitations in distinguishing which patients will benefit most from additional iron. Several novel anemia therapies, including hypoxia-inducible factor stabilizers, prolyl hydroxylase inhibitors, and dialysate-delivered iron supplements, have been developed and may offer options for alternative anemia management. However, the safety and efficacy of these agents in children with CKD has yet to be assessed.",
keywords = "Anemia, Erythropoiesis-stimulating agent, Hemoglobin, Hepcidin, Iron-restricted erythropoiesis",
author = "Meredith Atkinson and Warady, {Bradley A.}",
year = "2017",
month = "4",
day = "15",
doi = "10.1007/s00467-017-3663-y",
language = "English (US)",
pages = "1--12",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Anemia in chronic kidney disease

AU - Atkinson, Meredith

AU - Warady, Bradley A.

PY - 2017/4/15

Y1 - 2017/4/15

N2 - Anemia is common and associated with adverse outcomes in children with chronic kidney disease (CKD). Many factors contribute to declining hemoglobin as CKD progresses, but impaired production of erythropoietin by failing kidneys is a central cause. Hepcidin-mediated iron restriction also contributes to anemia by downregulating both intestinal iron absorption and release of stored iron for erythropoiesis. The core components of anemia management remain erythropoiesis-stimulating agents (ESA) and iron supplementation, but despite these therapies, a substantial number of children remain anemic. Although escalating ESA dose to target higher hemoglobin has been associated with adverse outcomes in adults, no trials have investigated this association in children, and maintaining hemoglobin levels in a narrow range with conservative ESA dosing is challenging. Judicious use of iron supplementation can enhance the response to ESAs, but the iron storage markers most commonly used in clinical practice have limitations in distinguishing which patients will benefit most from additional iron. Several novel anemia therapies, including hypoxia-inducible factor stabilizers, prolyl hydroxylase inhibitors, and dialysate-delivered iron supplements, have been developed and may offer options for alternative anemia management. However, the safety and efficacy of these agents in children with CKD has yet to be assessed.

AB - Anemia is common and associated with adverse outcomes in children with chronic kidney disease (CKD). Many factors contribute to declining hemoglobin as CKD progresses, but impaired production of erythropoietin by failing kidneys is a central cause. Hepcidin-mediated iron restriction also contributes to anemia by downregulating both intestinal iron absorption and release of stored iron for erythropoiesis. The core components of anemia management remain erythropoiesis-stimulating agents (ESA) and iron supplementation, but despite these therapies, a substantial number of children remain anemic. Although escalating ESA dose to target higher hemoglobin has been associated with adverse outcomes in adults, no trials have investigated this association in children, and maintaining hemoglobin levels in a narrow range with conservative ESA dosing is challenging. Judicious use of iron supplementation can enhance the response to ESAs, but the iron storage markers most commonly used in clinical practice have limitations in distinguishing which patients will benefit most from additional iron. Several novel anemia therapies, including hypoxia-inducible factor stabilizers, prolyl hydroxylase inhibitors, and dialysate-delivered iron supplements, have been developed and may offer options for alternative anemia management. However, the safety and efficacy of these agents in children with CKD has yet to be assessed.

KW - Anemia

KW - Erythropoiesis-stimulating agent

KW - Hemoglobin

KW - Hepcidin

KW - Iron-restricted erythropoiesis

UR - http://www.scopus.com/inward/record.url?scp=85017426469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017426469&partnerID=8YFLogxK

U2 - 10.1007/s00467-017-3663-y

DO - 10.1007/s00467-017-3663-y

M3 - Article

C2 - 28412770

AN - SCOPUS:85017426469

SP - 1

EP - 12

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

ER -